NightWare

NightWare is a prescription digital therapeutic system designed to reduce sleep disturbance associated with Nightmare Disorder and nightmares related to post-traumatic stress disorder (PTSD). The company's flagship product is the first and only FDA-cleared Class II digital therapeutic specifically indicated for nightmare-related sleep disturbance in adults 22 and older. The system leverages Apple products and proprietary algorithms to deliver adaptive interventions that respond to individual patient sleep patterns without waking patients. NightWare received FDA Breakthrough Device designation in 2020, reflecting unmet clinical need and preliminary evidence of substantial improvement on clinically significant endpoints. Safety and efficacy are supported by ongoing randomized, double-blind, placebo-controlled clinical trials, including a pivotal study at Walter Reed. The therapy requires no drug interactions, integrates with existing PTSD and nightmare treatments, and demonstrates clinically meaningful improvement within two weeks of initiation. The company serves both healthcare professionals and patients directly, providing clinical evidence, educational resources, and professional support materials to facilitate adoption across mental health, sleep medicine, and trauma care settings.